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Abstract
Retinoblastoma (Rb) is the most common primary intraocular malignancy in 
children with an incidence from 1:15,000 to 1:20,000 live births. It can present as 
a unilateral or bilateral involvement of the eyes. It is generally induced by biallelic 
mutation of the RB1 tumor suppressor gene that leads to malignant transformation 
of primitive retinal cells. The most common presentation is leukocoria, followed by 
strabismus. The initial assessment and future treatment of such tumor should be 
based on the laterality, the stage of the tumor, and the presenting age of the child. 
In general, the primary target of therapy is to preserve the child’s life. However, pre-
serving the globe and preserving vision should be achieved whenever it’s possible. 
Retinoblastoma treatment has evolved from enucleating the affected globe to also 
involving external beam radiation therapy, cryotherapy, laser photocoagulation, 
thermotherapy, brachytherapy, and chemotherapy (intravitreal, intra-arterial, and 
systematic). This chapter is intended to discuss briefly the clinical presentation of 
Rb, as well as a comprehensive review about the evolution and current treatment 
modalities with a focus on cases with low-risk features.
Keywords: retinoblastoma, management, enucleation, 
external beam radiation therapy, brachytherapy, thermotherapy,  
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1. Clinical presentation and diagnosis
The clinical presentation of retinoblastoma can be variable depending on the 
stage of the tumor. However, the most common presenting symptom overall is 
abnormal white reflection from one or both pupils [1]. This can be observed grossly 
by the naked eye and is termed as leukocoria. The second most common presen-
tation of retinoblastoma is strabismus, which results from sensory deprivation 
when the tumor involves the central vision [2]. Less commonly, uveitis, glaucoma, 
hyphema, iris heterochromia, and orbital cellulitis can also be presenting signs for 
retinoblastoma [3]. A more advance and late presentation may result in proptosis 
and orbital swelling [4]. Any of the mentioned clinical presentations in a child 
should prompt detailed clinical exam including dilated fundus examination. 
Typically, it shows unifocal or multifocal white vascularized retinal mass with or 
without tumor seeding. Different imaging modalities can be performed to aid in 
the diagnoses of retinoblastoma. The most easy and readily available modality is 
ultrasound. It can be helpful in the detection of intraocular mass characteristic 
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(height, thickness, and depth) and the presence of heterogeneity and calcification. 
Computed tomography (CT) is more sensitive in detecting intraocular calcifica-
tion and delineating the mass. However, CT scan raises the concern of developing 
secondary malignancies in cases with germ line mutation due to radiations [5]. 
Magnetic resonance imaging (MRI) is currently the preferred imaging modality of 
choice for most ophthalmologists. MRI is considered the best for detecting optic 
nerve involvement and extraocular extension [6]. Other diagnostic procedures like 
cerebrospinal fluid (CSF) analysis and cytology are particularly performed when 
there is evidence of optic nerve involvement grossly or microscopically based on 
histopathologic examination after enucleation. Bone marrow biopsy is indicated 
for bone marrow metastasis based on clinical exam or blood work-up. Diagnosis 
of retinoblastoma should be based on clinical examination that is supported by 
imaging techniques. However, differentiating retinoblastoma from other condi-
tions like persistent hyperplastic primary vitreous (PHPV), Coats’ disease, or 
toxocariasis can be challenging [7–11]. Different classifications have been proposed 
for retinoblastoma staging throughout the past decades, including TNMH (tumor, 
node, metastasis, heritable trait) cancer staging for the American Joint Committee 
on Cancer (AJCC), Reese-Ellsworth classification system (R-E), and International 
Intraocular Retinoblastoma Classification (IIRC) [12–16]. The International 
Intraocular Retinoblastoma Classification or International Classification of 
Retinoblastoma (ICRB) have been widely accepted by ophthalmologists since they 
were first introduced in 2003, to predict the outcomes following chemoreduction 
for retinoblastoma [15, 16] (Table 1 and Figure 1).
Group Subgroup Reference Features
A Very low 
risk
Small tumor • RB ≤3 mm (in basal dimension)
• Al least 3 mm away from the foveola and 1.5 mm 
from the optic nerve
• No vitreous or subretinal seeding is present
B Low risk Larger tumor
Macula
Juxtapapillary
Subretinal fluid
• RB >3 mm (in basal dimension)
• Macular location (≤3 mm to foveola)
• Juxtapapillary location (≤1.5 mm to optic nerve)
• Additional subretinal fluid (≤3 mm from margin)
• No vitreous or subretinal seeding is present
C Moderate 
risk
Focal seeds • Focal subretinal and/or vitreous seeds ≤3 mm from 
the tumor
D High risk Diffuse seeds • Diffuse subretinal and/or vitreous seeds >3 mm 
from the tumor
E Very high 
risk
Extensive 
retinoblastoma
• Extensive retinoblastoma occupying >50% of globe 
or any of the following:
• Secondary neovascular glaucoma
• Tumor anterior to anterior vitreous face or touching 
the lens
• Diffuse infiltrating retinoblastoma
• Massive intraocular hemorrhage
• Aseptic orbital cellulitis
• Phthisis bulbi
Table 1. 
International intraocular retinoblastoma classification.
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2. Management
Management of retinoblastoma is complex and requires a multidisciplinary team 
approach that includes an ophthalmologist, pediatric oncologist, radiation oncolo-
gist, pathologist, geneticist, social worker, nurses, and others. The primary goal of 
treatment is to save the child’s life and then to salvage the globe and optimize the 
vision if possible. A multimodal therapeutic option for retinoblastoma is avail-
able, which ranges from focal therapies like laser photocoagulation, cryotherapy, 
thermotherapy, and plaque radiotherapy to enucleation or chemotherapy for more 
advance cases. The decision for choosing a treatment option is depending on several 
factors including the laterality, tumor size and histopathologic feature, the age and 
general health of the child, and the family desires.
3. Enucleation
Enucleation is the preferred option for most children presenting with advance 
tumor (group E eyes), especially if unilateral [17–21]. Other indications for enucle-
ation are failure of all possible effective therapies, active tumor in an eye with no 
visual potential, anterior segment invasion, secondary neovascular glaucoma, 
and when the visualization of the tumor is compromised due to corneal opacity, 
cataract, or vitreous hemorrhage [22]. Enucleation is rarely indicated for bilateral 
retinoblastoma due to devastating functional limitation that follows such decision. 
The goal during enucleation is to obtain as much optic nerve as possible (usu-
ally 8–12 mm) to make sure that the surgical margin is free from tumor [23, 24]. 
Surgeons should avoid perforation of the globe during the procedure to minimize 
the potential risk of tumor seeding into the orbital tissue [25]. Histopathologic 
evaluation post enucleation allows for evaluation of high-risk features that requires 
additional chemotherapy. These features include retrolaminar optic nerve invasion, 
Figure 1. 
Retinoblastoma tumors, according to the international intraocular retinoblastoma classification, and their 
response to treatments.
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choroidal invasion, scleral and orbital invasion, and anterior chamber seeding 
[26–28]. At the time of enucleation, an orbital implant is placed to ensure proper 
growth of the orbit and allows for free movement of the prosthesis when attaching 
the extraocular muscles to the implant [4, 29]. Many different orbital implants can 
used and are generally divided to porous and nonporous implants. The most com-
monly used are porous implants, hence allowing vascular growth in the tiny pores 
within the implant. This can serve in the stabilization of the implant while minimiz-
ing the risk of exposure and extrusion or infection [4, 25].
4. External beam radiation therapy (EBRT)
External beam radiation therapy is an important modality used in the treatment 
of retinoblastoma. However, due to serious adverse effects, it has fallen out of use 
and became preserved for moderately advanced disease where retinoblastoma is 
refractory or progressive after chemotherapy to salvage the eye from enucleation. 
EBRT techniques have improved overtime, and new methods aim to eliminate the 
disease and minimize normal tissue exposure to avoid any adverse effects [30–33].
The main EBRT techniques used in treating retinoblastoma are photon or elec-
tron radiation therapy (ERT), intensity-modulated radiation therapy (IMRT), and 
proton radiation therapy (PRT). IMRT and PRT allow for more conformal radiother-
apy options in addition to a unique physical property of PRT. Rather than traversing 
the target, protons stops at energy-dependent depth and with a reduced exit dose to 
almost zero where it reduces the injury to uninvolved structures and limit the radia-
tion beams to a specific area. This physical property has shown to decrease unwanted 
adverse effects, making PRT become superior to photon therapy [30, 31].
EBRT treatment sessions are usually scheduled over a period of weeks where 
multiple small fractions of radiation are delivered via an external machine targeting 
the lesion. This increases tumor sensitivity to radiation by allowing time for reoxy-
genation and reassortment of cell cycle. It also spares normal tissues by allowing 
time for repair in between fractions. Conversely, PRT is delivered in one or a few 
large fractions, but to small discrete volumes, hence minimizing the volume of 
surrounding irradiated normal tissue [30, 34].
The outcome of patients who were treated with EBRT has been studied over the 
past decades. Enucleation was ultimately required in 18–37.5% of eyes, and local 
failure after radiotherapy was similar between PRT and ERT. Vision was preserved 
in most of the cases with an outcome showing up to 70% of patients having no or 
mild visual impairment. Moderate visual impairment is seen in 10–23% of eyes, 
whereas poor or no useful vision was in 20–41.7% of non-enucleated eyes. The best 
visual outcomes are noted in patients with early stages that spared the optic disc, 
macula, and fovea, suggesting that the location of tumors has an impact of visual 
outcome even after PRT [35–38].
Acute toxicities that can be seen after therapy sessions include local erythema of 
the skin, hyperpigmentation, erythema of the conjunctiva, and loss of eyelashes. 
Patients treated with PRT had a similar rate of acute toxicities, compared to patients 
treated with ERT. Cataracts were the most common long-term complication in eyes 
treated with EBRT. Other ocular complications noted are radiation retinopathy, 
glaucoma, neovascularization, vitreous hemorrhage, retinal detachment, strabis-
mus, and less common toxicities [35–38].
The hypothalamus-pituitary axis is known to be affected in EBRT as it is exposed 
to radiation beams. Growth hormone deficiency and thyroid-stimulating hormone 
abnormality are noted in patients treated with EBRT. However, due to PRT physical 
properties that eliminate the radiation to midline structures, these adverse effects 
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are noted to be less than in conventional radiation therapy. Therefore, endocrinopa-
thies were almost limited in patients treated with PRT [38, 39].
Another adverse effect reported is craniofacial deformities where the facial and bony 
structures tend to be affected in EBRT. These include hypoplasia, hyperpigmentation, or 
soft tissue fibrosis. Long-term dentofacial anomalies have also been reported [36, 38, 40].
Risk of new cancers is a major concern in retinoblastoma patients treated with 
radiotherapy. The cumulative incidence of a second cancer at 50 years after diag-
nosis of retinoblastoma was 36% for hereditary retinoblastoma. Bone, nasal cavity, 
connective and soft tissue, and other neoplasms have been associated in retino-
blastoma survivors who received EBRT. Osteosarcomas and soft tissue sarcomas 
are the most common tumors reported in irradiated patients reaching up to 76% 
of all cancer in ages younger than 25 years old. On the other hand, in unilateral 
retinoblastoma patients who did not receive radiation, sarcomas did not occur. In 
addition, the subsequent risk of cancer was noted to be higher in irradiated patients 
than nonirradiated whether the patients had hereditary or non-hereditary disease. 
Also, elevated doses of radiation were associated with increased risk of subsequent 
tumors. However, no subsequent cancers were noted among hereditary patients 
treated with chemotherapy. Furthermore, a comparison between photon and 
proton radiotherapy techniques was done and it showed that the 10-year cumulative 
incidence of malignancies was significantly higher in photon therapy compared 
to proton therapy. Therefore, patients treated with radiotherapy should have long 
follow-ups regardless of the modality used [32, 33, 41].
Lastly, the quality of life was observed, and no difference was noted between 
children and their parents regarding the quality-of-life outcomes compared to the 
general population [38].
5. Brachytherapy
Brachytherapy is a form of radiotherapy where a source of radiation is placed 
inside or next to the treatment area. In retinoblastoma the radioactive implant is 
placed on the sclera corresponding to the tumor base and fixed surgically to irradiate 
the tumor. Implantation technique requires excellent surgical skills and is applied 
under general sedation where the implant is fixed on the sclera and maintained 
for few days and removed with the patients remaining in the hospital during the 
entire treatment [42]. Iodine-125 and Ruthenium-106 are the most common radio-
active agents to be used in intraocular lesions. Other agents can be used such as 
Ruthenium-106, Palladium-103, Strontium-90, Cobalt-60, and Iridium-192 [42, 
43]. Like EBRT, the use of brachytherapy has been limited to progressive disease and 
to preserve the eye from enucleation. However, brachytherapy offers less spread of 
radiation, and its complications that can be associated with EBRT can be prevented 
where damage of normal tissue can be minimized which can lead to deformities 
and more importantly reduce the risk of radiation-induced second cancers [42, 44, 
45]. Brachytherapy can be used as primary modality to treat retinoblastoma where 
the tumor is found solitary and located anterior to the equator as per the American 
Brachytherapy Society-Ophthalmic Oncology Task Force (ABS-OOTF) recommenda-
tions. As for secondary treatment where retinoblastoma failed to respond to other 
treatment modalities, it can be used irrespective of its location [43]. Brachytherapy is 
also an effective method that can be used post enucleation to prevent recurrence [46].
Plaque brachytherapy achieved tumor control in 83–89% of cases in some stud-
ies reaching up to 88% when used as a primary modality and appears to be the best 
choice in patients who failed laser photocoagulation, thermotherapy, cryotherapy, 
or chemoreduction, but it is less successful in patients who failed EBRT [45, 47, 48]. 
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Reirradiation of local recurrence with brachytherapy can be considered as an option 
to salvage the eye from enucleation, and it may provide tumor control and eye pres-
ervation [48]. Complications related to radiation included radiation retinopathy, 
maculopathy, papillopathy, cataract, and glaucoma. Fortunately, no second cancers 
related to plaque brachytherapy were reported in the literature [45, 47–50].
Visual acuity in patients was found to be good in 64% and poor in 24–32% of 
non-enucleated eyes who were treated with plaque radiotherapy. The poor visual 
outcome was mainly associated with macular lesions, macular edema, vitreous 
hemorrhage, and phthisis bulbi. It appears that there is no significant difference 
whether brachytherapy was used as a primary or secondary modality in visual 
outcome [45, 47].
In many centers, Iodine-125 is used as the standard isotope for plaque brachy-
therapy. This is due to the physical properties like its half-life, low energy, adequate 
dose distribution, and ease of shielding [42, 43]. In a study, the use of Iodine-125 
as salvage treatment in 84 recurrent lesions after chemoreduction is reported. It 
showed 95% control in those who failed chemoreduction and 100% control in 
patients who failed a combination of chemoreduction and EBRT. Complications 
were higher in patients who received EBRT and included papillopathy, vitreous 
hemorrhage, cataract, and neovascularization [50].
Ruthenium-106 has some advantages over Iodine-125 where it’s lower in cost, 
has longer half-life, and is safer in terms of radioprotection. It has shown tumor 
control achievement up to 73%, and some studies achieved eye preservation 
in 89% of cases. Local recurrence with Ruthenium-106 is noted to reach 6.3%. 
Complications of Ruthenium-106 are generally similar to those found in other 
radiation modalities such as proliferative retinopathy which can lead to vitreous 
hemorrhage, radiation maculopathy radiation optic neuropathy, exudative retinal 
detachment, neovascularization, neovascular glaucoma, and cataracts. Previous 
treatment with EBRT was shown to be associated with increased risk of some com-
plications such as optic neuropathy, retinal detachment, and cataracts. However, 
studies of efficacy of Ruthenium-106 in retinoblastoma compared to Iodine-125 are 
limited in the literature [51–54].
6. Focal therapy
Focal therapy in treatment of retinoblastoma is used either alone in small retino-
blastomas (group A or B) (1, 2 laser) or after chemoreduction, usually after two or 
three cycles, or for small recurrent tumors or subretinal seeds [55–57].
7. Transpupillary thermotherapy (TTT)
Thermotherapy is based on increasing the tissue temperature from 45 to 60°C to 
induce a cytotoxic effect, through applying an 810-nm diode laser below the coagu-
lative threshold to prevent retinal vessels from coagulation, and it can be used alone 
for small retinoblastomas that are 3 mm in diameter without vitreous or subretinal 
seeds [57, 58]. In a study of 91 tumors, 92% of the tumors that were 1.5 mm in diam-
eter were controlled with thermotherapy alone [59]. Out of 188 treated by thermo-
therapy, complete regression of the tumor was achieved in (85%) 161 tumors, where 
the mean tumor size is 3.0 mm base and 2.0 mm thickness [60]. Complications of 
transpupillary thermotherapy include iris atrophy, cataracts, tumor seeding into the 
vitreous, retinal fibrosis, transition, and vascular occlusion.
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8. Laser photocoagulation
Laser photocoagulation is aimed to diminish blood supply of tumor. This type of 
treatment is used for small (4 mm in diameter and 2 mm in thickness) and posterior 
tumors. Argon or diode laser or a xenon arc is used but not directly on tumor tissue; 
instead it is aimed to coagulate the blood vessels that supply the tumor.
Retinal detachment, retinal vascular occlusion, retinal traction, and preretinal 
fibrosis can be a complication of this type of treatment [61–63].
9. Cryotherapy
Cryotherapy induces rapid decrease (freeze) of tumor tissue, and this will cause 
damage to the tumor blood vessel endothelium and lead to vascular thrombosis, 
which results in tumor ischemia and infarction. It is used as primary treatment for 
small equatorial and peripheral retinal tumors (<3.5-mm base and <2-mm thick-
ness). Treatment protocol is based on three applications for each session every 
4–6 weeks until complete regression of the tumor. Complications of cryotherapy 
include retinal tears and detachment, proliferative vitreoretinopathy, and chorio-
retinal atrophy. Cryotherapy can be used 2–3 hours before chemotherapy adminis-
tration, and that can increase the permeability of blood retinal barrier and increase 
the effect of chemotherapy [61, 63].
10. Chemotherapy
Chemotherapy is considered as one of the most important modalities used to 
treat retinoblastoma. It has been used as a main therapeutic modality achieving 
tumor control in up to 78% with the elimination of the need for enucleation as well 
as EBRT and its risk of developing second new cancers [64]. Chemotherapeutic 
agents can be delivered via four main routes which are intravenous chemotherapy, 
intra-arterial chemotherapy (IAC), intravitreal chemotherapy, and periocular 
chemotherapy. The most common chemotherapeutic agents used are vincristine, 
etoposide, and carboplatin. This (VEC) regimen is the most popular combination 
preferred by many experts, and this stems from its proven effect on neuronal 
tumors in the pediatric age group as well as its good penetration into the eye [65]. 
Melphalan is considered as the best and most effective agent in intra-arterial 
chemotherapy, and it is the most commonly used [66]. Tumor control, chemo-
reduction, and outcome differ from one modality and route of administration to 
another. Outcome also depends on the ICRB where chemotherapy can be success-
ful in 100% in group A and it drops as low as 50% in groups D and E. Visual out-
come can be maintained with a visual acuity of 6/60 or better in around two-thirds 
of patients [16, 67]. Adverse effects of chemotherapy observed are different from 
one modality to another. For instance, common side effects seen with systemic 
chemotherapy include transient pancytopenia, fever, and alopecia. Intra-arterial 
chemotherapy complications are attributed either to the procedure itself or to the 
chemotherapeutic agent. It can result in endovascular complications, allergy, and 
hematoma at the site of entry. IAC can also result in ocular vascular complications. 
Neutropenia is another important complication noted in IAC. Among the most 
frequent side effects of intravitreal chemotherapy are retinal pigment epithelium 
changes, iris depigmentation and atrophy, chorioretinal atrophy with vitreous 
hemorrhage, and retinal detachment. Fortunately, second primary malignancy 
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risk in chemotherapy is almost eliminated compared to EBRT which has made 
chemotherapy more superior in treating retinoblastoma [68–75]. A more detailed 
information is mentioned in the chapter entitled Retinoblastoma Management: 
Advances in Chemotherapy.
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